SPT Labtech integrates recent acquisitions into unified brand and portfolio

12/10/2021 SPT Labtech, a global leader in the design and development of automated instrumentation and consumables for life science applications, unveils new branding that brings together its technologies with those from recent acquisitions into a single entity. The merged portfolio and positioning reflect SPT Labtech’s commitment to harnessing the ingenuity and product development track record... Read more

Danaher Releases 2021 Sustainability Report; Building A Strong Foundation Of Sustainability

Danaher Releases 2021 Sustainability Report; Building A Strong Foundation Of Sustainability WASHINGTON, Oct. 12, 2021 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”), the global science and technology innovator, today released its 2021 Sustainability Report and highlighted the meaningful progress it has achieved in building a strong foundation of sustainability. Rainer Blair, President and CEO said,... Read more

Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 27, 2021

Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 27, 2021 WALTHAM, Mass., Oct. 11, 2021 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2021 before the market opens on Wednesday, October 27, 2021, and will hold... Read more

SciAps to revolutionize in-field analysis of lithium and rare earth elements

OCTOBER 10, 2021GEOCHEMISTRY, NEWS & PRESS, REE AND STRATEGIC METALS SciAps new family of handheld LIBS and XRF are built for exploration, production and recycling of lithium and REEs for the electric vehicle and strategic metals markets. SciAps, already a global leader in handheld analyzers for fossil fuel-based energy industries, now delivers ground-breaking technology to the emerging... Read more

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer’s disease

Gantenerumab is an investigational antibody in Phase III development for early Alzheimer’s disease (AD) Gantenerumab is the first and only anti-amyloid antibody being investigated for subcutaneous administration in late-stage trials for the treatment of AD Ongoing Phase III GRADUATE programme with gantenerumab is anticipated to deliver a comprehensive data set with expected readout in the... Read more